BPC-157: The Body’s Own Repair Peptide
What Is BPC-157?
BPC-157 (sequence GEPPPGKPADDAGLV) is a synthetic pentadecapeptide modeled on a protective compound found naturally in human gastric juice. It has been studied for decades by researchers at the University of Zagreb led by Dr. Predrag Sikiric, originally as a candidate treatment for inflammatory bowel disease, before its broader healing effects drew attention in sports-recovery circles.
How It’s Proposed to Work
Laboratory studies describe BPC-157 as interacting with the nitric oxide system to support new blood vessel formation, protect the gut lining, and help organize tissue at injury sites, including effects on genes involved in early collagen formation. These mechanisms are best documented in the gastrointestinal tract; musculoskeletal applications are extrapolated from a smaller, more recent body of animal work.
What the Research Shows
BPC-157’s strongest evidence base comes from the gut. Developed clinically as PL 14736, it reportedly reached a Phase II human trial for ulcerative colitis; a 2012 review describes that trial and reports no dose-limiting toxicity in the researchers’ own testing. That trial data is more than a decade old and we have not located a published completion report or FDA action following it, so we treat it as historical context rather than proof of a marketed drug.
-
Sikiric et al. · Inflammopharmacology, 2024
Decades of Rodent Data on Gut Protection and Organ Injury
A 2024 review from the same research group summarizes decades of rodent data on gut protection and organ injury.
Read the study on PubMed → -
Masnec et al. · 2025
Corneal Ulcer Treatment Mechanism
A November 2025 review links BPC-157’s mechanism to corneal ulcer treatment.
Read the study on PubMed → -
Smoday et al. · 2026
Vascular Injury After Adrenalectomy (Rat Study)
A May 2026 rat study examines vascular injury after adrenalectomy.
Read the study on PubMed → -
Mendias & Awan · Sports Medicine, 2026
Peptides in Sports Medicine: Evidence, Safety & Regulatory Status
An April 2026 narrative review in Sports Medicine assesses BPC-157 alongside other approved and unapproved peptides, weighing animal-model tissue-repair data against the current scarcity of rigorous human safety evidence.
Read the review on PubMed →
Regulatory & Safety Status You Should Know
BPC-157’s bulk-substance nomination was previously placed in the FDA’s Category 2 list for compounding, the category reserved for substances the agency views as raising significant safety risks. As of the FDA’s most recent update, content current as of April 22, 2026, that nomination has been withdrawn by the nominator, which removes it from the active Category 2 table, though this is not the same as FDA approval for human use.
Review the FDA’s substance-by-substance notes →Regulatory Update — July 2026
The picture moved on this front. At its July 23–24, 2026 meeting, the FDA’s Pharmacy Compounding Advisory Committee (PCAC) voted 8–6 (with one abstention) to recommend that BPC-157 be added to the Section 503A bulk drug substances list for pharmacy compounding. Importantly, this is a non-binding recommendation, not FDA approval: the FDA has not finalized a decision and BPC-157 remains unapproved for human use as of this update. We will revise this page again if the agency issues a final determination.
Read the FDA advisory committee meeting page →Our Commitment to Credibility
We link every claim above to its primary source, flag when evidence is decades old or animal-only, and revisit this page as new studies or regulatory decisions publish. If you are considering BPC-157, discuss it with a licensed physician and check the FDA’s current list before sourcing it through any pharmacy.
Related research tool
Working with lyophilized BPC-157 in the lab? Use our peptide reconstitution calculator to determine concentration and the exact draw volume from your vial amount, bacteriostatic water, and target research dose.
Related Research Material
Octagon Labs supplies BPC-157 (5 mg) research peptide for laboratory use only. Researchers studying tendon and soft-tissue recovery often pair it with TB-500 (Thymosin Beta-4) or the combined Wolverine Stack (BPC-157 + TB-500). For research use only; not for human consumption.